Posted in FINANCE FDA Approves Bluebird’s Gene Therapy for Rare Blood Disease August 18, 2022 The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient. …read more https://www.wsj.com/articles/fda-approves-bluebirds-2-8-million-gene-therapy-for-rare-blood-disease-11660759942?mod=pls_whats_news_us_business_f